A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson’s Disease

BACKGROUND AND AIMS: Entacapone, one of the most common drugs distributed among patients with Parkinson’s disease, is a peripherally acting catechol-O-methyltransferase (COMT) inhibitor that is used in addition to levodopa to control symptoms. However, there have been negative effects reported again...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Shih-Chen, Lee, Chung-Han, Hsieh, Yi-Chen, Wu, Pei-Hua, Lin, Sheng-Hsuan, Wang, Hsiuying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cellular and Infection Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022099/
https://www.ncbi.nlm.nih.gov/pubmed/35463646
http://dx.doi.org/10.3389/fcimb.2022.837019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022099/
https://www.ncbi.nlm.nih.gov/pubmed/35463646
http://dx.doi.org/10.3389/fcimb.2022.837019

Ejemplares similares